title: The long-term outcome of hip replacement in adults with juvenile idiopathic arthritis: the influence of steroids and methotrexate.
abstract: Juvenile idiopathic arthritis (JIA) is a chronic disease of childhood; it causes joint damage which may require surgical intervention, often in the young adult. The aim of this study was to describe the long-term outcome and survival of hip replacement in a group of adult patients with JIA and to determine predictors of survival for the prosthesis. In this retrospective comparative study patients were identified from the database of a regional specialist adult JIA clinic. This documented a series of 47 hip replacements performed in 25 adult patients with JIA. Surgery was performed at a mean age of 27 years (11 to 47), with a mean follow-up of 19 years (2 to 36). The mean Western Ontario and McMaster Universities osteoarthritis index questionnaire (WOMAC) score at the last follow-up was 53 (19 to 96) and the mean Health Assessment Questionnaire score was 2.25 (0 to 3). The mean pain component of the WOMAC score (60 (20 to 100)) was significantly higher than the mean functional component score (46 (0 to 97)) (p = 0.02). Kaplan-Meier survival analysis revealed a survival probability of 46.6% (95% confidence interval 37.5 to 55.7) at 19 years, with a trend towards enhanced survival with the use of a cemented acetabular component and a cementless femoral component. This was not, however, statistically significant (acetabular component, p = 0.76, femoral component, p = 0.45). Cox's proportional hazards regression analysis showed an implant survival rate of 54.9% at 19 years at the mean of covariates. Survival of the prosthesis was significantly poorer (p = 0.001) in patients who had been taking long-term corticosteroids and significantly better (p = 0.02) in patients on methotrexate.
authors.affiliation: Musculoskeletal Unit, Newcastle Hospitals NHS Trust, Freeman Hospital, High Heaton, Newcastle-upon-Tyne NE7 7DN, UK. amalviya@nhs.net
authors.forename: A
authors.initials: A
authors.lastname: Malviya
authors.forename: L C
authors.initials: LC
authors.lastname: Walker
authors.forename: P
authors.initials: P
authors.lastname: Avery
authors.forename: S
authors.initials: S
authors.lastname: Osborne
authors.forename: D J
authors.initials: DJ
authors.lastname: Weir
authors.forename: H E
authors.initials: HE
authors.lastname: Foster
authors.forename: D J
authors.initials: DJ
authors.lastname: Deehan
mesh_terms: D000293:Adolescent; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy / Q000601:surgery*; D019644:Arthroplasty, Replacement, Hip / Q000379:methods*; D002648:Child; D019544:Equipment Failure Analysis; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D011475:Prosthesis Failure / Q000187:drug effects; D016059:Range of Motion, Articular; D012044:Regression Analysis; D012720:Severity of Illness Index; D013256:Steroids / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D013256:Steroids; D008727:Methotrexate